C-O7HAmitochondrial transplantation, mitochondrial augmentation, biomarkers
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Minovia mitochondrial transplantation, mitochondrial augmentation, biomarkers
Minovia is a clinical-stage biotech developing mitochondrial augmentation therapy, an ex vivo cell-therapy approach that adds healthy donor mitochondria to a patient’s own CD34+ hematopoietic stem/progenitor cells before reinfusion. The strongest support is platform plausibility, company-linked preclinical work, early human safety signals in rare mitochondrial disease, and active Phase 2/Phase 1b programs in Pearson syndrome and low-risk myelodysplastic syndrome; the main weaknesses are tiny open-label datasets, heavy reliance on company-authored or press-release style sources, unresolved manufacturing and scalability risk, and a failed de-SPAC financing route in early 2026.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Minovia — Far from goals · Bottom quartile. Derived deterministically from 16 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (7 programs at undisclosed).…
Source: Deterministic